Guardant Health, Inc. (GH)

NASDAQ: GH · IEX Real-Time Price · USD
46.25
+1.79 (4.03%)
At close: Jun 24, 2022 4:00 PM
44.00
-2.25 (-4.86%)
After-hours: Jun 24, 2022 6:07 PM EDT
4.03%
Market Cap 4.71B
Revenue (ttm) 391.09M
Net Income (ttm) -419.24M
Shares Out 101.92M
EPS (ttm) -4.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,036,741
Open 44.76
Previous Close 44.46
Day's Range 44.01 - 46.27
52-Week Range 27.65 - 133.82
Beta 0.72
Analysts Buy
Price Target 120.08 (+159.6%)
Earnings Date Aug 4, 2022

About GH

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect... [Read more...]

Industry Health Care Providers & Services
IPO Date Oct 4, 2018
Employees 1,373
Stock Exchange NASDAQ
Ticker Symbol GH
Full Company Profile

Financial Performance

In 2021, GH's revenue was $373.65 million, an increase of 30.32% compared to the previous year's $286.73 million. Losses were -$405.67 million, 59.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for GH stock is "Buy." The 12-month stock price forecast is 120.08, which is an increase of 159.63% from the latest price.

Price Target
$120.08
(159.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by ...

Why Shares of Guardant Health Dropped 33.6% in May

The biotech company is down more than 61% this year.

Guardant Health to Participate in Upcoming June Investor Conferences

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. ...

First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d'Hebron Institute of Oncology

PALO ALTO, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d'Hebron Institute of Oncology (VHIO), one of Europe's leadi...

Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Onco...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (...

Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Pro...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant...

Why Guardant Health Stock Is Crashing Today

Investors reacted negatively after the company's Q1 update.

Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance

Guardant Health Inc's (NASDAQ: GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driv...

Guardant Health (GH) Reports Q1 Loss, Lags Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of 1.63% and 0.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health Reports First Quarter 2022 Financial Results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data se...

Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Ri...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the availability of Shield™, the company's first blood-based test for the de...

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health to Participate in the BofA Securities 2022 Healthcare Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare ...

This Chart Is Why I'm Not Worried About Guardant Health

The leading innovator in the liquid biopsy space has huge addressable markets ahead of it.

Guardant Health to Report First Quarter Financial Results on May 5, 2022

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2022 after market ...

Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American As...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating the ability of the company's investigational next-...

2 Top Biotech Stocks to Buy in April

These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.

Other symbols: TXG

Guardant Health Announces Partnership with Epic to Streamline Access to Company's Broad Portfolio of Cancer Tests

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation's most widely used comprehensive heal...

Why Guardant Health Stock Soared Nearly 10% Higher Today

Negativity surrounding the precision oncology company might be overblown.

Looking for Growth? Check Out These 2 Diagnostics Stocks

Hospitals can't do without their products, and demand is rising.

Other symbols: LNTH

Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today provided the following statement regarding a lawsuit filed by Illumina that seeks t...

Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted ...

Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Re...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data from its broad portfolio of blood tests at the A...

Why Guardant Health Jumped Nearly 5% on Tuesday

The health diagnostic company's cancer biomarker test is slowly but surely moving into the mainstream.

Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagn...